iBio, Inc. (IBIO)
NASDAQ: IBIO · Real-Time Price · USD
1.200
-0.010 (-0.83%)
Oct 27, 2025, 9:57 AM EDT - Market open
iBio, Inc. Revenue
In the fiscal year ending June 30, 2025, iBio, Inc. had annual revenue of $400.00K with 77.78% growth. iBio, Inc. had revenue of $200.00K in the quarter ending June 30, 2025, with 14.29% growth.
Revenue (ttm)
$400.00K
Revenue Growth
+77.78%
P/S Ratio
31.76
Revenue / Employee
$20,000
Employees
20
Market Cap
24.31M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 400.00K | 175.00K | 77.78% |
| Jun 30, 2024 | 225.00K | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | 1.88M | -487.00K | -20.54% |
| Jun 30, 2021 | 2.37M | 733.00K | 44.75% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
IBIO News
- 4 days ago - iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - GlobeNewsWire
- 6 days ago - iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025 - GlobeNewsWire
- 7 weeks ago - iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - iBio Announces Closing of $50 Million Public Offering - GlobeNewsWire
- 2 months ago - iBio Announces Pricing of $50 Million Public Offering - GlobeNewsWire
- 2 months ago - iBio Announces Proposed Public Offering - GlobeNewsWire
- 4 months ago - iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results - GlobeNewsWire
- 4 months ago - iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call - GlobeNewsWire